Blood Pressure Drug Litigation Sees Some Warranty Claims Advance

Patients and insurers alleging that recalled generic valsartan blood pressure drugs were tainted with probable carcinogens may proceed with many of their warranty claims, the federal court overseeing multidistrict litigation said.

Plaintiffs say the drugs are tainted with the industrial byproducts NDMA and NDEA. The MDL includes individual personal injury suits alleging the drug caused cancer, and proposed class suits.

They raise about three dozen claims on behalf of hundreds of individuals, as well as would-be statewide and nationwide classes of consumers against more than 40 defendants including manufacturers, wholesalers, and pharmacies. There are three separate master complaints seeking personal ...